Synucure Therapeutics inc. is a Canadian biotechnology company conducting research in brain degenerative disorders. Synucure was founded in 2021 with the key objective to pursue the promising and robust pre-clinical work of Dr. Francesca Cicchetti on a repurposed drug called Cysteamine which demonstrated, in various animal and cell models, that it could prevent and/or reverse a number of features related to Parkinson’s disease (PD).  

In addition to the promising role of Cysteamine as a Disease Modifying Therapy (DMT) in Parkinson, Dr. Cicchetti and her colleagues are conducting research on patented blood biomarkers, of which the main objective is to provide clinicians with a more rapid and precise diagnostic and stratification tool using a simple blood test.